News

Here's the blind spot: ◉ Antimicrobial Resistance (AMR) diagnostics market growing >6.5% CAGR to reach $6.7B by 2030 ◉ But >50% of antibiotic prescriptions still happen without proper testing ◉ Rapid phenotypic AST (antimicrobial susceptibility testing) now returns results in ~4.5-7 hours (not 1-2 days) ◉ Yet payment still rewards treatment volume more than diagnostic-guided outcomes ⇶This is the missing link: You can't fix the antibiotic incentive problem without fixing diagnostic incentives first. The math that changes everything: ⊛ Rapid diagnostics cut inappropriate prescribing by ~20-60% in trials (test- and setting-dependent). The breakthrough model emerging: ⇉ Diagnostic-therapeutic subscriptions: pay for the decision, not just the drug ⇉ AI-guided precision prescribing with resistance-adjusted dosing ⇉ Real-time stewardship dashboards feeding back to pull incentive eligibility for new antibiotics ⇉ Companion diagnostics scoped from Day 1 of antibiotic R&D - and required at launch. 🧐 The companies cracking this code: Selux Diagnostics, Inc, Accelerate Diagnostics, bioMérieux, and emerging players building AI-first platforms.